FDA warns against combination of malaria drug and Gilead’s remdesivir

0
17
The U.S. Food and Drug Administration on Monday issued a warning to healthcare providers against administering malaria drug hydroxychloroquine or chloroquine in combination with Gilead Sciences’ experimental COVID-19 drug, remdesivir.

Go to Source
Author: